Next Article in Journal
PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor
Previous Article in Journal
Cyclodextrin Inclusion Complexes with Antibiotics and Antibacterial Agents as Drug-Delivery Systems—A Pharmaceutical Perspective
 
 
Article

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts

1
Research Laboratory for Biomechanics and Implant Technology, Department of Orthopedics, Rostock University Medical Centre, 18057 Rostock, Germany
2
Department of Systems Biology and Bioinformatics, University of Rostock, 18057 Rostock, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Tomáš Etrych
Pharmaceutics 2022, 14(7), 1390; https://doi.org/10.3390/pharmaceutics14071390
Received: 22 April 2022 / Revised: 1 June 2022 / Accepted: 27 June 2022 / Published: 30 June 2022
(This article belongs to the Section Biologics and Biosimilars)
Interleukin (IL-) 6 is a key factor in the inflammatory processes of rheumatoid arthritis. Several biologic agents target the IL-6 signaling pathway, including sarilumab, a monoclonal antibody that blocks the IL-6 receptor and inhibits IL-6-mediated cis- and trans-signaling. A careful analysis of the IL-6 signaling blockade should consider not only inflammatory processes but also the regenerative functions of IL-6. The purpose of this study was to investigate whether inhibition of the IL-6 receptors affects differentiation of human primary osteoblasts (hOB). The effects of sarilumab on viability and the differentiation capacity in unstimulated osteoblasts as well as after stimulation with various IL-6 and sIL6-R concentrations were determined. Sarilumab treatment alone did not affect the differentiation or induction of inflammatory processes in hOB. However, the significant induction of alkaline phosphatase activity which was observed after exogenous IL-6/sIL-6R costimulation at the highest concentrations was reduced back to baseline levels by the addition of sarilumab. The IL-6 receptor blockade also decreased gene expression of mediators required for osteogenesis and bone matrix maintenance. Our results demonstrate that concomitant administration of the IL-6 receptor blocker sarilumab can inhibit IL-6/sIL-6R-induced osteogenic differentiation. View Full-Text
Keywords: Interleukin 6; sarilumab; soluble IL-6 receptor; antagonism; human osteoblasts; osteogenic differentiation Interleukin 6; sarilumab; soluble IL-6 receptor; antagonism; human osteoblasts; osteogenic differentiation
Show Figures

Figure 1

MDPI and ACS Style

Klinder, A.; Waletzko-Hellwig, J.; Sellin, M.-L.; Seyfarth-Sehlke, A.; Wolfien, M.; Prehn, F.; Bader, R.; Jonitz-Heincke, A. Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts. Pharmaceutics 2022, 14, 1390. https://doi.org/10.3390/pharmaceutics14071390

AMA Style

Klinder A, Waletzko-Hellwig J, Sellin M-L, Seyfarth-Sehlke A, Wolfien M, Prehn F, Bader R, Jonitz-Heincke A. Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts. Pharmaceutics. 2022; 14(7):1390. https://doi.org/10.3390/pharmaceutics14071390

Chicago/Turabian Style

Klinder, Annett, Janine Waletzko-Hellwig, Marie-Luise Sellin, Anika Seyfarth-Sehlke, Markus Wolfien, Franziska Prehn, Rainer Bader, and Anika Jonitz-Heincke. 2022. "Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts" Pharmaceutics 14, no. 7: 1390. https://doi.org/10.3390/pharmaceutics14071390

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop